目前斑秃的治疗

Q2 Medicine

Journal of Investigative Dermatology Symposium Proceedings Pub Date : 2020-11-01 DOI:10.1016/j.jisp.2020.04.004

Maria K. Hordinsky

{"title":"目前斑秃的治疗","authors":"Maria K. Hordinsky","doi":"10.1016/j.jisp.2020.04.004","DOIUrl":null,"url":null,"abstract":"<div><p>The number of alopecia areata (AA) clinical trials with Jak inhibitors of cytoplasmic tyrosine kinases, including Jak1, Jak2, Jak3, and tyrosine-protein kinase has increased significantly since the last Research Summit. This fact means that the conversation about current treatments for AA now also needs to include a discussion of traditionally used off-label therapies as well as evolving therapies as with Jak inhibitors.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"20 1","pages":"Pages S28-S30"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1087002420300046/pdfft?md5=6c9e1cfe2e7e9d55ae79970f85c92386&pid=1-s2.0-S1087002420300046-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Current Treatment of Alopecia Areata\",\"authors\":\"Maria K. Hordinsky\",\"doi\":\"10.1016/j.jisp.2020.04.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The number of alopecia areata (AA) clinical trials with Jak inhibitors of cytoplasmic tyrosine kinases, including Jak1, Jak2, Jak3, and tyrosine-protein kinase has increased significantly since the last Research Summit. This fact means that the conversation about current treatments for AA now also needs to include a discussion of traditionally used off-label therapies as well as evolving therapies as with Jak inhibitors.</p></div>\",\"PeriodicalId\":54791,\"journal\":{\"name\":\"Journal of Investigative Dermatology Symposium Proceedings\",\"volume\":\"20 1\",\"pages\":\"Pages S28-S30\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1087002420300046/pdfft?md5=6c9e1cfe2e7e9d55ae79970f85c92386&pid=1-s2.0-S1087002420300046-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Investigative Dermatology Symposium Proceedings\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1087002420300046\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigative Dermatology Symposium Proceedings","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1087002420300046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

自上次研究峰会以来，使用Jak1、Jak2、Jak3和酪氨酸蛋白激酶等胞质酪氨酸激酶抑制剂的斑秃(AA)临床试验的数量显著增加。这一事实意味着，关于AA目前治疗方法的讨论现在还需要包括对传统的非适应症治疗方法的讨论，以及对Jak抑制剂的新疗法的讨论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Current Treatment of Alopecia Areata

The number of alopecia areata (AA) clinical trials with Jak inhibitors of cytoplasmic tyrosine kinases, including Jak1, Jak2, Jak3, and tyrosine-protein kinase has increased significantly since the last Research Summit. This fact means that the conversation about current treatments for AA now also needs to include a discussion of traditionally used off-label therapies as well as evolving therapies as with Jak inhibitors.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Investigative Dermatology Symposium Proceedings 医学-皮肤病学

自引率

0.00%

发文量

期刊介绍： Journal of Investigative Dermatology Symposium Proceedings (JIDSP) publishes peer-reviewed, invited papers relevant to all aspects of cutaneous biology and skin disease. Papers in the JIDSP are often initially presented at a scientific meeting. Potential topics include biochemistry, biophysics, carcinogenesis, cellular growth and regulation, clinical research, development, epidemiology and other population-based research, extracellular matrix, genetics, immunology, melanocyte biology, microbiology, molecular and cell biology, pathology, pharmacology and percutaneous absorption, photobiology, physiology, and skin structure.